Business Wire

ESI Group: A More Inclusive and Safer Industry for Women and Everyone Thanks to Simulation

8.3.2023 23:35:00 EET | Business Wire | Press release

Share

Regulatory News:

ESI Group (Paris:ESI) (ISIN Code: FR0004110310, Symbol: ESI) is a global partner in simulation and virtual prototyping software for various industries. The company is committed to promoting gender equality through various actions, including the recruitment of women and their professional development within the industry. In addition, the Group is advocating for a swift change in legislation to allow the use of virtual prototyping in certification tests in the automotive industry, with the ultimate goal of ensuring the safety of all users, irrespective of their gender or body shape.

According to the World Economic Forum, women are 47% more likely than men to be seriously injured in a car accident. The study of the Insurance Institute of Highway Safety (IIHS) published in 2021 underlines that women have a mortality rate 20 to 28% higher than men during a road accident, a situation explained in part because of the poor consideration of female morphology in crash tests.

Florence Barré, Women@ESI General Delegate and Chief of Staff to Cristel de Rouvray, CEO of ESI Group: " The role of digitization in ensuring highway safety cannot be overstated. By incorporating diverse morphologies in simulations, virtual prototyping can better protect the entire population. Although the automotive industry has widely adopted virtual prototyping, the use of virtual human models that account for a wide range of morphologies remains optional. Therefore, legislators must take an active role in encouraging the systematic adoption of these practices to ensure optimal safety for all users, regardless of their gender or body shape."

Crash tests that no longer correspond to the reality of society

The current system that we have inherited today has remained relatively unchanged for the past 50 years. Mandatory physical tests in the automotive industry no longer reflect the reality of modern society. Shockingly, only one out of the five dummy models used in crash tests until recently was designed to represent female physiology. This particular model, created in the late 1980s, was based on just 5% of the female population and was mostly used in the front and rear passenger positions, with very little consideration for the driver's seat in regulatory test scenarios.

Towards a major breakthrough?

In a significant milestone for both technological advancement and industry awareness, a team of Swedish engineers announced the creation of the world's first female crash test dummy late last year. This achievement highlights the increasing importance of gender inclusion and equality, which are rapidly gaining traction worldwide. However, the question remains: how can we ensure that this breakthrough is accessible and available to all?

The use of digital human models

ESI Group firmly believes that regulatory evolution is necessary to encourage the adoption of agile and inclusive methods, rather than relying solely on physical tests and prototypes as reference tools for passive safety certifications. Moving towards a more virtual and diverse approach enables the representation of current driving practices, including various morphotypes and passenger positions.

Virtual prototyping allows for flexible parameter modifications and facilitates testing on all morphotypes, enabling even more comprehensive results. Additionally, simulation can incorporate morphological diversity in a faster and less expensive manner. Many of ESI Group's industrial partners are already utilizing virtual prototyping to address this challenge. In fact, ESI Group was the first to perform a virtual crash test on the Volkswagen Polo back in 1985, allowing major automotive OEMs to conduct virtual testing of their prototypes instead of costly and time-consuming physical tests.

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1000 people around the world and reported 2022 sales of €130 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com.

Follow ESI LinkedIn | Facebook | Twitter | YouTube

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28

Aline Besselièvre
aline.besselievre@gmail.com
+33 6 61 85 10 05

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye